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Cardiac Pacing in the 1980s: Treatment and Techniques in Transition
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The pacemaker of the 1980s is designed to maintain
atrioventricular synchrony through dual-chamber pac-
ing. This pacemaker is multiprogrammable and capable
of telemetric transmission of biologic, electronic and
electrophysiologic data. Several developments have made
this therapeutic modality possible: 1) the cumulative sur-
vival rate of many lithium-battery pacemakers exceeds
95% at 5 years; 2) lead and connector problems are rare;
3) atrial and ventricular electrode malfunctions occur in
less than 2% of implants; and 4) new introducer tech-
niques have simplified implantation (mortality and ma-
jor morbidity rates are 0.5 and 0.4%, respectively). With
multiprogrammability, pacemaker function can be op-
timized for the patient's needs, and about 20% of reo-
perations can be avoided.
Ninety-six dual-chamber (DOD) pacemakers, 55 of
which have been followed up for more than 3 months,
have provided trouble-free performance and have yielded
salutary clinical results, particularly when implanted to
replace previous ventricular inhibited units. Problems
The scope of cardiac pacing has changed dramatically in
the past 20 years. From the simplicity of fixed-rate ven-
tricular pacing for patients with complete heart block and
Stokes-Adams syndrome. we have progressed to the com-
plexity of multiprogrammable dual-chamber pacemakers with
provisions for control of tachyarrhythmia, physiologic
adaptability and transcutaneous interrogation. Ordinarily such
an advance would be a source of pride, much as we have
been proud of technologic progress in other fields, from cars
to space satellites and from adding machines to supercom-
puters. However, as with supersonic transport, the space
shuttle and home computers, questions now arise concerning
usefulness, applicability and cost. To answer such questions
about the practice of pacing, and to establish risk/benefit
and cost/benefit ratios, it is necessary to examine a variety
of aspects.
From the Department of Surgery and The Pacemaker Center, Newark
Beth Israel Medical Center, Newark, New Jersey.
Address for reprints: Victor Parsonnet, MD, Director of Surgery, New-
ark Beth Israel Medical Center, 201 Lyons Avenue, Newark, New Jersey
07112.
© 1983 by the American College of Cardiology
with these pacemakers have included unusual pacing
electrocardiograms, pacemaker eccentricities, program-
mer maintenance, pacing and follow-upcomplexitiesand
costs.
In the 1980s, effort will be required to find a balance
between rapidly evolvingtechnology and the clinical need
for complex pacing systems. From 1978to 1981, the rate
of pacemaker implantation grew from 309 to 513 im-
plants per million population per year, and there are
now approximately 500,000 patients with implanted
pacemakers living in the United States. Indications for
pacing are ill-defined, because in many cases the as-
sessment of clinical response to pacing is largely subjec-
tive, lacking satisfactory quantitative indexes. This dec-
ade will be a time of reappraisal of the extent of clinical
applicability of new techniques, particularly the multi-
programmable dual-chamber system which, after 3 years
of clinical trial, shows promise of being the predominant
pacemaker of the immediate future.
Proliferation of Pacemaker Implantation
First and foremost is the impact of modern engineering on
the device, and the consequent widespread increase in pace-
maker applications for a variety of cardiac conditions. Such
proliferation is clearly evident from data obtained in five
surveys of pacing practice in the United States conducted
by the senior author beginning in 1969 (Fig. 1) (1-4 and
1981 survey, in preparation). In 1979, Irnich estimated that
the rate of pacemaker implantation would level off at about
330 per million population (lrnich W, personal communi-
cation). However, in 1981 there were approximately 118,000
new implants in the United States, or 513 new implants per
million population. Compared with 71 per million popu-
lation in 1969, this represents a net growth of about 623%
in 12 years. At the same time, pulse generator replacements
decreased from 33,000 in 1978 to 23,300 in 1981, a re-
duction of 29%. There are now approximately 500,000 pa-
tients in the United States with implanted pacemakers, or
one pacemaker for every 460 persons (1981 survey). These
figures, although approximate, are astounding. A discussion
of the state of the art of pacing must certainly focus on the
0735-1097/83/010339-16$03.00
340 J AM COLL CARDIOL
1983;1:339-54
PARSONNET AND BERNSTEIN
- NUMBER OF NEW IMPLANTS PER
500 MILLION POP 100
_.- NUMBER OF LIVING PATIENTS 5.
450 ( IN THOUSANDS)
/
90
--~ % REPLACEMENTS IN TOTAL
400 IMPLANTS / 80
350 / 70
~ 300 / 60-' ~~ 'Ii
i:: 250 / 50 &1
~ ---~-, ~200 40 ...
/ "
150 /' " 3D
/' .....
100
./.
20.-......
50 -'- 100 0
1969 '70 '71 '72 '73 '74 '75 '76 '77 '7B '79 '80 1981
YEAR 6.
Figure 1. Total implants and pulse-generator replacements plotted over a
12 year period together with the number of living pacemaker patients. The
proportion of replacements has decreased markedly with improvements in
device longevity. POP. = population.
issue of pacemaker utilization, and on whether such utili-
zation is justifiable.
Paeessaker utilization. It was recently claimed that at
least 25% of the pacemakers now implanted in patients in
the United States are needless (5). This judgment was based
on the following considerations:
1. Published reports (6-9) have concluded that some pace-
makers are unnecessary and can be removed without
harm, either because they were never truly needed or
because the original rhythm abnormality had disap-
peared. Morse et al. (6) described a systematic method
for determining whether a pacemaker could be removed
safely. Kowey et al. (7) reported in an abstract that 10
of 32 patients referred for evaluation remained free of
symptoms after explantation of their pacemakers. Ami-
kam et al. (9) removed 10 pacemakers that appeared
unnecessary (but 2 were later replaced for recurrent
bradycardia) .
2. A report (10) indicated that peer review at one hospital
reduced the frequency of pacemaker implantation by half.
3. In an unpublished report, Lindenberg and Levine com-
pared the quality of work at their own institution, where
at worst 3% of implants may have been unnecessary,
with that of another local hospital (unnamed) where 24%
of implants may have been unnecessary.
4. A 1979 report (10) indicated that new pacemakers were
implanted in patients in the United States at a rate almost
twice that of any other country (309 per million popu-
lation in the United States compared with 183 per million
population in Sweden) (11). No conclusions were drawn
as to whether pacemaker implantation was too frequent
in the United States or too infrequent elsewhere. Selzer
(12), in a recent letter to The New England Journal of
Medicine, favored the former judgment. *
A retrospective analysis of the discharge diagnoses of
2,222 patients who had pacemakers implanted in the
State of Maryland during 1979 and 1980 concluded that
22.7% of the pacemakers were unnecessary and that the
necessity for an additional 13.4% was questionable (5).
The charts themselves were not reviewed. In a letter to
the Secretary of Health and Human Services, the authors
recommended that a second opinion be mandated "as a
condition for reimbursement" and that peer review or-
ganizations should establish a set of standard indications
for implantation. (These recommendations were reported
widely in the national press in July 1982.)
Rumors suggested that manufacturers manipulated some
physicians to implant pacemakers through unethical mar-
keting practices (14,15). Although no hard evidence for
this practice has ever been published, we know that some
manufacturers have at times entertained physicians lav-
ishly at major medical conventions, often against the
express wishes of the congress (16). One pacemaker
manufacturer has even brought suit against another.
charging unethical practices (14).
Although there have been pleas for standards in pacing and
commentary about rising costs. these items constitute the
principal basis for the recent wave of adverse criticism di-
rected toward physicians and industry alike. If such reports
and rumors. some verging on scandal, are accepted at face
value, they may have a major impact on pacing practices
in this country.
To establish whether or not a pacemaker is worth the
money, or if pacemakers are being implanted needlessly,
one must consider the following aspects of pacing:
I. Device reliability and longevity (pulse generators and leads)
2. Devicecomplexity and programmability
3. Surgical techniques and risks
4. New pacing modalities
5. Surveillance techniques
6. Costs
7. Clinical need and indications
Pacemaker Technology
Pulse generators. The modern pacemaker is a small device
weighing approximately 50 g, hermetically sealed in a metal can,
powered by a lithium-chemistry battery capableof lasting 5 to 15
years or more and noninvasively programmable in many of its
operating parameters. The most prevalent pacemaker operates in
*It is of interest that in 1981, the implantation rate in France reached
440 per million population, well above the implantation rate in the United
States 4 years earlier (13). This suggests that in 1978, when physicians in
the United States were suspected of overzealous pacemaker implantation,
physicians in other countries might not have been implanting pacemakers
frequently enough.
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Figure 2. Schematic representation of the Cordis 415A
(Gemini) DDD pulse generator now undergoing clinical
trials. The programmable parameters are indicated, and
the number of choices for each is given in parentheses.
AMPL. = amplitude; AV = atrioventricular; CH 2 =
channel 2; MAX. = maximum; MIN. = minimum; PD
= pulse duration; VENT. = ventricular.
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the ventricular demand mode (VVI). * It is programmable in rate
and output and costs approximately $2,500. (Virtually no fixed-
rate pacemakers are implanted in the United States any longer.
even though there may be a need for such simple and inexpensive
devices elsewhere in the world.) The more complex pacemakers
now on the market are dual-chamber units. programmable to eight
or nine different modes of operation and capable of a wide range
of output and sensitivity values. One such pacemaker has more
than 42 million possible combinations of programmable settings
(Fig. 2). These pacemakers are capable of telemetric transmission
of information regarding their identity. programmed settings and
battery condition, and in some cases provide electrogram telemetry
as well. These units cost about $5.000.
Tremendous flexibility in pulse generator design is being achieved
with "software-organized" pacemakers, in which signal-process-
ing, decision-making and control circuits are largely replaced by
programming of an implanted microcomputer. Such devices could
conceivably undergo extensive functional redesign years after being
implanted (18.19). Automatic implantable defibrillators have reached
the clinical validation stage (20).
Despite the complexity of the modern pulse generator. its greater
longevity is clearly documented in an ongoing five-center study
(21). Although two or three models developed in the past 8 years
have performed poorly, cumulative actuarial survival curves show
that approximately 90% continue to function well at 84 and 96
months (Fig. 3). When pulse generator circuits of the past used
discrete electronic components. the addition of more components
increased the chance of electronic failure. This is not true of the
modern pacemaker with large-scale ihtegrated circuits (22). Dual-
chamber pacemakers are not as long-lived as the single-chamber
units. but data show that at 36 months. 87% of the Intermedics
259-0j units continue to function, as do 100% of the Medtronic
5992 units at 48 months (21).
*VVI and other standard symbolic representations of pacing modes
used in this paper are taken from a code prepared in 1974 by the Inter-
SocietyCommission for Heart Disease Resources (17).
Electrodes and leads. Innovations in lead design and fabri-
cation, particularly the multifilar helical-coil steel wire. have made
the occurrence of lead fractures and other causes of late lead failure
a rarity (23). In the past, early electrode malfunction (a definition
that includes dislocation. malposition. perforation and high thresh-
old) accounted for 5 to 10% of early reoperations, but it is now
infrequent (24). Tined delayed-fixation and screw-in active-fixa-
tion electrodes have reduced lead malfunctions to less than 2%
(1981 survey).
Atrial-electrode survival was more of a problem in the past.
New designs. particularly the fixed-J shape and the screw-in elec-
trodes. have improved results to the point that the reported cu-
mulative survival of the Medtronic 6957J (Bisping) lead is 100%
at 29 months. and that of the 6990U and 6991 U leads combined
is 91% at 38 months (Fig. 4) (25-30 and Parsonnet V, unpublished
data).
Instead of silicone rubber insulation. many of the new leads
use polyurethane. a tough plastic with high tensile strength. Poly-
urethane is also slippery. so that it is possible to manipulate two
leads in the same vein without dislodging one electrode while
manipulating the other. This quality alone has greatly simplified
the implantation of dual-chamber pacemakers.
Stimulation thresholds for these new atrial electrodes are al-
most as low as ventricular thresholds. which raises questions about
the belief that atrial thresholds are by nature higher than ventricuiar
thresholds. Our own data and those of others (26) indicate that
acute atrial thresholds are about 0.6 V at a 1.5 ms pulse duration,
and that P wave amplitudes generally exceed 2 mV (Table I).
These values are well within the output and sensing capabilities
of most modern pulse generators.
For a time it appeared that Pellathanei degradation. in the
form ofsurface cracking and insulation breaks. would be a limiting
factor in the use of such leads (31). However. new fabrication
tPellathane is the trade name of a group of polyurethanes produced
by Upjohn. Inc.. Kalamazoo. Michigan.
342 J AM COLL CARDIOL
1983: I:339-54
PARSONNET AND BERNSTEIN
Figure 3. Actuarial survival of pulse generators as a
function of power source. The remarkable longevity
of lithiumbatteriescompared with that of the mercury-
zinc batteries is evident.
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techniques and different forms of polyurethane may have dimin-
ished this problem. Medtronic reports that there were 44 instances
of polyurethane failure in more than 110,000 implants (0.04%).
but no further failures have been reported since December 1981,
when manufacturing practices were modified (Stokes K, personal
communication). Cordis Corporation has seen no failures in more
than 8,000 implants (Leetmaa B, personal communication). Poly-
urethane defects are sufficiently rare and should not pose a sig-
nificant risk of early failure of lead-wire insulation.
The connectors between leads and the pulse generator have
become more or less standardized in two sizes of the pin-and-
socket type, and are at most a minor source of early or late pacing
failure (1981 survey). Further improvements in electrode design
have produced coaxial and in-line bipolar leads, with "one-hole"
connectors to facilitate bipolar pacing and to provide the option
of unipolar or bipolar operation (29.32-36).
Other device-related problems. The more common troubles
have included undersensing of cardiac signals and sensing of my-
opotentials and external electromagnetic radiation. Undersensing ,
particularly of P waves, has become increasingly rare because of
improved electrodes and sensitivity programming. Oversensing,
on the other hand. particularly sensing of myopotentials of the
pectoral muscles underlying a unipolar pulse generator. has been
a more serious problem. (Sensing of myopotentials almost never
occurs with bipolar units.) It has been shown that sustained de-
liberate flexion of the pectoral muscles will inhibit 75% of inhibited
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Table 1. Mean Acute Pacing Thresholds and Electrographic
Amplitudes of Delayed- and Active-Fixation Atrial and
Ventricular Electrodes
Atrial Ventricular
Electrodes Electrodes
Medtronic Medtronic Medtronic
69571 6991U and 6990U* 6957
Sample Size 49 70 51
Thresholdst
Voltage (V) 0.62 0.68 0.43
Current (rnA) 0.67 0.76 0.43
Electrograms
(mV P-P1t 2.77 2.50 11.42
*Tip electrode only. tMeasured at 1.5 ms. :j:p-P = peak to peak.
pulse generators, and that in approximately 5% of cases, pace-
maker inhibition by myopotentials may produce symptoms during
normal activities (37-39 and 1981 survey). This problem can be
avoided by critical sensitivity programming, programming the pulse
generator to a triggered mode or converting the pacemaker to a
bipolar unit by programming or replacement. Sensing of electrical
signals from outside the body (electromagnetic interference) is
extremely rare.
Multiprogrammability. Many pacing parameters can be al-
tered by noninvasive programming, including mode, output, sen-
sitivity, refractory periods, minimum and maximum rates, unipolar
or bipolar operation, hysteresis and tachyarrhythmia response. In
some units almost all of the operating parameters are program-
mable, and specialfunctions suchasautomaticstimulation-threshold
testing and data or electrographic telemetry can be activated by
programming. The primary usefulness of multiprogrammability
lies in its capability of achieving optimal physiologic benefit and
of extending pulse generator life. Programming also makes it pos-
sible to analyze and correct problems that might otherwise require
surgical intervention. Our experience (40) has shown that proper
use of programming features may avoid more than j 7% of re-
operations; this figure is similar to those of others (41-44) and
Parsonnet V, unpublished data). Programming also requires much
more elaborate follow-up and record-keeping, as well as mainte-
nance of an external programmer for every pacemaker that is being
followed up in the clinic. Problems arise through programming
eccentricities, inadvertent misprogramming and (occasionally un-
documented) programming by others.
Modern pacemakers and their associated leads and connectors
have proved to be highly reliable devices. Once implanted they
will provide many years of trouble-free performance. Multipro-
grammability may reduce the need for pacemaker reoperations,
but it increases the complexity of pacemaker management and
follow-up.
Implantation Techniques and Operative Risk
The transvenous approach is preferred by 95% of the phy-
sicians in the United States. Myocardial implantation is
reserved for complex cases in which the appropriate veins
are thrombosed or infected and for the times when the heart
is exposed during open-heart surgery (4 and 1981 survey).
The percutaneous introducer was used for entrance into
the subclavian vein by 50% of the physicians implanting
pacemakers in 1981 .. a few used it almost exclusively (1981
survey). Although pneumothorax was encountered as a com-
plication of this technique in a few cases, serious compli-
cations were rare and no deaths were reported in this survey.
A separate query of II physicians who had used the in-
troducer in approximately 2,500 cases disclosed II serious
complications (0.4%) and two introducer-related deaths
(0.08%) (Parsonnet V, unpublished data).
The survey also revealed that early reoperations for elec-
trode problems occurred in less than 2% of cases, and that
other complications of surgical technique, particularly in-
fections, were rare. Even with dual-chamber pacing, early
reoperations were uncommon. The average hospital stay for
patients with a first implant was less than 5 days, and for
those undergoing pacemaker replacement the average stay
was less than 3 days; many surgeons recommend only I
day admission for pulse generator replacements. In our in-
stitution, operative mortality was less than 0.5% over the
past 5 years, and most of the deaths were directly related
to the severity of associated conditions, such as renal failure,
cerebrovascular disease and congestive heart failure. Thus,
even though the average pacemaker patient is approximately
70 years old, the mortality and morbidity rates of pacemaker
implantation are so low that the risk to the patient is not an
important consideration in calculating risk/benefit ratios.
Dual-Chamber Pacemakers:
Experience With DDD Units
The most important and significant recent advance in pacing
to affect the state of the art has been the development of
dual-chamber (DDD) pacing. DDD pacemakers stimulate
the atrium and ventricle sequentially when atrial rates are
slow (DVl), and pace the ventricles synchronously with the
P wave when atrial rates are faster (VDD). At abnormally
fast atrial rates, the atrial sensing circuit no longer tracks the
atrial impulses one-for-one and the ventricular rate falls to
an acceptable level, either abruptly or gradually. Thus atrio-
ventricular (AV) synchrony is maintained over a wide range
of rates.
Methods
In 1981, several models of DDD pacemakers became available
for validation in the United States: the Cordis 233D (Sequicor),
the Medtronic 7000 (Versatrax)* and the Biotronik Diplos. (These
were approved by the Institutional Review Board at the Newark
Beth Israel Medical Center on July 23. 1981, November 20. 1980
*Considerable experience had already been gained in Europe with the
earlier version of the Medtronic 7000 (45-471.
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and July 2, 1981, respectively.) The sensing, output, sensitivity
and refractory-period settings are programmable in these models
to varying degrees, and almost all programmers have a "stat set"
button that resets the pacemaker to the VVI mode at safe output
and sensing values. The pacemakers differ from one another in
various ways, as do their corresponding programmers (Tables 2
and 3). None of the current generation of these pacemakers has
telemetry capabilities, but the next generation will provide ex-
tended telemetry. No special criteria for patient selection were
mandated except for the contraindication of frequent supraven-
tricular arrhythmias and rare conditions such as the giant left atrium
in patients with mitral stenosis.
Implantations were almost always performed transvenousiy un-
der local anesthesia. New leads were inserted through an intro-
ducer or, rarely, through an exposed large cephalic vein. The two
leads were most commonly inserted through two separate subcla-
vian punctures or by a single-puncture technique (48-50). In some
cases, two leads were passed through the same introducer. If an
existing electrode was found to have satisfactory threshold and
sensing performance, it was left in place. Most of the new elec-
Tllble 2. Characteristics of Three DOD Pulse Generators*
trodes were of the Bisping screw-in type with polyurethane in-
sulation (Table 4). When leads were too long, they were shortened
to 10 em from the entrance site into the pectoral muscles and
appropriate adapters were attached. Threshold and sensing mea-
surements were made by methods described elsewhere (51) and
records were kept of all values. In cases of sick sinus syndrome,
simple studies of sinoatrial node function and AV conduction were
also performed, including rapid atrial pacing to assess the Wenck-
ebach rate, corrected sinus node recovery time and response to
carotid sinus massage. Electrophysiologic and hemodynamic stud-
ies were performed in three of our cases to compare the effec-
tiveness of DOD (or DVI or VDD) with that of VVI pacing. In
all but the first few cases, ventriculoatrial (VA) conduction times
were measured at various ventricular pacing rates.
Wounds were closed with absorbable continuous subcuticular
sutures. Most patients were discharged within 3 or 4 days after
being given detailed postoperative instructions. In all cases, pro-
gramming to appropriate settings was performed at the time of
implantation, again on the day before discharge from the hospital,
and definitively 4 to 6 weeks later in the follow-up clinic.
Dimensions (mm)
Mass (g)
Specific gravity
Type
Battery
Electrodes
Projected
longevity (yr)
Programmable parameters
DOD mode
Fixed parameters
Eccentricities
Drawbacks
Advantages
Biotronik Diplos
L = 56, W = 51, T = 13
56
1.5
Voltage source
Li-Ag2Cr04
Unipolar
4.5 (000, 72 beats/min. 0.5 ms)
Min. rate, AV delay. atrial, pulse
width, atrial sens.
Pulse amplitude, vent. pulse width.
vent. sens., refr. periods, rate
limit, magnet mode. magnet rate
Escape interval after sensed R wave
is AA, not VA
Limited programmability. esp. AV
delay & atrial refractory;
committed vent. output
Simplicity
Medtronic 7000 (Versatrax)
D = 56. T = 18.3
90
2.7
Voltage source
Li-I, 2.79 V. 3.5 A-h (idO p,A
Unipolar
8.8 (DOO. 70 beats/min, 0.5
ms)
Min. rate. max. rate. AV delay,
pulse width, sens.
Pulse amplitude. refractory and
blanking periods. magnet
mode. magnet rate. rate limit
Constant energy output. fast
recharge pulse, bigeminy
protection system. premature
vent. output after vent.
sensing early in AV delay
Large size. short atr. refractory
(high likelihood of PMT).
complexity of analysis
Threshold margin test.
uncommitted vent. output
Cordis 2330 (Sequicor)
L = 69. W = 56. T = 14
76
1.9
Current source
Li-I 4.2 V. 1.8 A-h
Unipolar
1.8 (000. 70 beats/min. 1.0
ms)
Min. rate, max. rate.
fallback response. fallback
rate, AV delay. pulse
width. sens .. atrial refr.
(indirect)
Pulse amplitude, refr. periods
(exc. atrial in 2: I block
mode), blanking period.
rate limit. magnet mode.
magnet rate
Atrial refractory controlled in
2: I block mode through
max. rate programming
Short life expectancy (much
longer in 2nd generation)
Indirectly programmable
atrial refractory (not prone
to reentrant
tachyarrhythmia):
uncommitted vent. output
'Comm~nts regarding eccentricities. drawbacks and advantages represent our own value judgments and should not be interpreted as the results of a formal survey.
AA = escape interval; atr. = atrial: AV = atrioventricular: D = diameter: exc. = except: L = length: Li-Ag,CrO, = lithium-silver chromate: Li-l = lithium-iodine:
max. = maximum; min: = minimum; PMT = pacemaker-mediated tachycardia; refr. = refractory: sens. = sensitivity; T = thickness: VA = ventriculoatrial escape
interval; vent. = ventricular; W = width.
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Table 3. Programmers Used With the DDD Pacemakers of Table 2*
Medtronic Censys Cordis 222 Cordis Prog. III
Size Semiportable Hand-held Hand-held
Operation Complex Simple except with Fairly simple
233D
Operator's
manual Complex Simple Complex
Display
legibility Fair to good Fair Fair to good
AC required For use For charging For charging
Sensitivity to
line voltage
variations ? No No
Printout Yes No Yes
Stat set Yes Only for 233D Yes
Special problems Channel not identified Too many cards and Cursor moves in only
in printout manipulations one direction;
inadvertent button-
pushing mayoccur
when hand-held
Confirmation of Yes No No
programming
'Value judgments are those of our clinical staff and should not be interpreted as results of a formal survey.
AC = alternating current.
Cordis Interactive
Mobile
Very simple
Fairly simple
Good
For use & charging
Yes
Yes
Yes
Wand lights
obscured on
patient's far side
Yes
Biotronik EPR 400
Hand-held
Simple
Simple
Good to excellent
No
No
No
No
Must line up with
pacemaker:
awkward: wand
Iights obscured
on patient's far
side
No
Results
From September 1981 to June 1982,55 DDD pacemakers of three
types were implanted. * There were 30 men and 25 women, av-
eraging 66.1 years of age (range 33 to 86); 34 (62%) of the implants
were primary and 21 (38%) secondary to replace existing single-
chamber pacemakers. The follow-up period ranged from 3 to 10
months.
The indications for implantation were high-grade AV block in
23 patients, sick sinus syndrome in 31 (3 with associated episodes
of ventricular tachycardia) and carotid sinus syndrome in I.
Early and late complications are listed in Table 5. Only one
lead reoperation was required as a result of technical error, when
the insulation of a shortened wire was stripped. There were no
malfunctions in any of the 48 new atrial leads (2 were in the stump
of an amputated atrial appendage) or in the 41 new ventricular
leads. Two late (nonelectrode) complications required no correc-
tive action.
There were six late deaths: three were related to the patient's
medical condition and three were sudden. A 72 year old man who
had an episode of syncope due to ventricular tachycardia on the
'By August 1982, a totalof 96 DDD pacemakers hadbeen implanted,
butonlythe first 55 hadbeenfollowed up longenough to justify inclusion
in this report. Among the recent cases was another model of a DDD
pacemaker implanted in nine patients: the Cordis 4I5A (Gemini). This
model has flexible programmability, especially in rate and in atrial and
ventricular refractory periods, and has a projected longevity of 12 years
at nominal settings. As of this writing, four more models of DDD pace-
makers of evengreater complexity havebeenreleased for validation trials.
According to the manufacturers, 3,500 DDD pacemakers have been im-
planted worldwide (Duffin E, Medtronic, Inc., and Leetmaa B, Cordis
Corp.; personal communications).
5th postoperative day died 4 months later. Both before and after
pacemaker implantation he had experienced numerous episodes of
ventricular tachycardia secondary to severe ischemic heart disease;
his death is not considered pacemaker-related, Another patient, a
72 year old man, died at home on the 6th postoperative day, and
a third patient, an 82 year old man, died 3 months after implan-
tation; neither pacemaker was retrieved and the causes of death
are unknown. In all three patients, frequent transtelephonic mon-
itoring of the electrocardiogram had revealed no pacing problems
within 2 weeks of death.
The final programmed mode settings are summarized in Table
6. Less than half of the Medtronic 7000 pacemakers were left in
the DDD mode (12 of 26), because the atrial refractory period
after a ventricular output is too short, permitting sensing of ret-
rograde P waves and pacemaker-reentrant, or pacemaker-me-
diated, tachycardia. Therefore, until we became more discrimi-
nating in pacemaker selection, choosing the Medtronic 7000
pacemaker only for patients with V.A. block, a change to the DVI
mode was required quite frequently. Pacemaker-mediated tachy-
Table 4. New Leads Implanted as Part of the DDD Study*
Chamber Type Number Comment
Atrium Medtronic 6957J 48 2 implants in atrial stump:
(Bisping) I late sensing problem
Ventricle Medtronic 6957 40 No problems
(Bisping)
Biotronik No problems
Screw-in
'Excluding four sets of epicardial leads implanted during open heart surgery.
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Table 5. Complications With DDD Pacing* Table 7. Final Pacemaker Programming at 4 to 6 Weeks
Type Number Action Parameter Value No. of Cases Comment
' Three of the 20 problems listed requ ired surgical intervention.
PMT = pacemaker- mediated tachycardia.
' More than half of the Medtroni c 7000 series required programming out of the
DOD mode to avoid pacemaker-mediated tachycardia. (This unit' , atrial channel is
refractory for only 155 ms after a ventricular output.)
Table 6. Mode Programming
Final Cordis Medtronic Biotronik
Settings 233D 7000 · Diplos Totals
ODD 20 12 6 38
OVI 2 14 0 16
VVI I 0 0 I
Totals 23 26 6 55
cardia was not encountered with the six Biotronik Diplos pace-
makers. and the few times it was seen in the Cordis 233D series
it was easily corrected by programming the tachycardia response
to the 2:I block mode and programming the maximum rate to an
appropriate value.
Th e output and sensi ng se ttings (Table 7 ) require littl e elab-
oration. Many values wereselected empirically. leaving widesafety
margins for capture and sensing. The AV delay was most com-
monly set to approximate the normalPR interval: the 250 ms setting
was used for patients whose AV conduction was normal and in
whom we wished to maintain the normal sequence of ventricular
activation.
Most of the patients experi en ced sym ptomatic relief. except for
one who had a single unexplained syncopal episode I month after
implantation. Two patients who had their VVI pacemakers re-
placed for severe pacemaker syndrome demonstrated the most
impressive benefit from DDD pacing. The first was a 74 year old
physician who had a left ventricular aneurysm and exertional dys-
pnea and angina associatedwith arteriosclerotic heart disease. VVI
pacing for I year had produceda mild but troublesome pacemaker
syndrome. With DDD pacing. his cardiac index rose from 2. 1 to
2.9 liters/min and the pacemaker syndrome disappeared entirely.
He remains well and comfortable after 8 months and has resumed
his medical practice.
Many left at 1.0 ms
were in 2330
series where lower
values were not
fi nely adjustable
Pacemakers in DVI
mode do not sense
in atrium
Some outputs were
not programmable
One pacemaker was
left in VVI mode
Settings not used in
OVI or VVI units
16
23
I
33
20
2
17
2
1
4
51
11
24
5
14
2
/3
31
8
1
8
24
3
I
Atrial 1.5
2.0
3.0
Ventricular 1.5
2.5
AV interval(ms) 150
165 or 175*
200 or 225*
250
Minimum rate (beats/min) 50
60
20
80
90
Maximum rate (beats/min) 100
125 or 130·
150
180
Sensing threshold (mV) 0 .75 to 1.2
Output pulse duration (rns) 0 .5
Atrial 1.0
1.5
Ventricular 0.5
1.0
1.5
' Where available parameter settings were not identical. similar values are combined.
The other patient was an 81 year old man with a severe pace-
maker syndrome and a hypersensitive carotid sinus. Preopera-
tively. carotid pressure applied with the patient in a standing po-
sition initiatedventricularpacing and near-syncope associated with
a decrease in systolic pressure from 180 to 80 torr. After DDD
pacing. a similar maneuver produced a slight decrease in blood
pressure but no symptoms (Fig. 5).
Comments
Clinical benefit. The clinical benefit of AV synchrony
is demonstrated most dramat ically in patients with one or
more symptoms of the pacemaker syndrome. Anyone who
had experien ced the thumping sensation of cannon A waves,
episodic spells of weakn ess or shortness of breath and loss
of vigor immed iately impro ved with restoration of AV syn-
chrony. The two cases just cited are typical examples of
this salutary effect. The subjective benefits of AV snychrony
were less obvious in patients receivi ng a first implant . per-
haps because they had no standard of comparison. However ,
several studies involving alternation of VVI and DVI (or
VDD or DOD) mode s, either for a few moments in the
catheterization laboratory or pacemaker cl inic, or for periods
of days or weeks. have demonstrated measurable improve-
Intermittent
Unexplained
Programmed o ut
Absorbed
All to DVI
All to DDD and 2:I block
Programmed to DVI
Programmed to DVI
Reoperation: atrial
electrode replaced
3
4
I
I
I
I
I
6
Early:
PMT
Medtronic 7000
Cordis 233D
Ventricular tachycardia
Lidocaine convulsion
Diaphragmatic stimulation
Pneumothorax
Intermittent sensing.
Cordis 233D
Adapter separation
Late:
Syncopal episode
Atrial fibrillation
(sick sinus syndrome)
Deaths
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CAROTID PRESSURE ------------'
Figure 5. A, Simultaneous recordings of the electrocar-
diogram (EeG, leads I, II and III), aortic blood pressure
(Ao) and pulmonary artery pressure (Pa), Note the oc-
currence of ventricular pacing and the decrease in aortic
pressure during carotid sinus massage. B, Beneficial ef-
fects after institution of sequential atrioventricular pacing
(see text).
180
B
ment in myocardial performance and clinical well-being
during periods of AV synchrony. Such clinical improvement
is particularly noticeable in patients with impaired ventric-
ular function, mitral stenosis or idiopathic hypertrophic sub-
aortic stenosis, and in relatively vigorous or athletic patients
(52-65).
Operative problems. Like others, we found that im-
planting dual-chamber pacemakers presented no unusual
technical difficulties. With experience we learned to implant
two wires simultaneously, one person positioning the ven-
tricular electrode while the other positioned the atrial elec-
trode. While threshold measurements and other tests were
being performed on one wire, the other electrode was seated
securely by advancing the fixation screw. The average op-
eration lasted less than I hour.
Pacemaker function. Stimulation thresholds and elec-
trographic amplitudes at the time of implantation have been
excellent, as have been the threshold values estimated grossly
by output programming at 4 to 6 weeks. There was only
one late intermittent atrial sensing failure that required
switching to the DVI mode. Tests of VA conduction, orig-
inally performed in the hope that they would assist in correct
pacemaker selection, did not prove to be valuable, because
five patients with apparent VA block developed bursts of
pacemaker-reentrant tachycardia. (Perhaps other such events
would have been found if all patients had been monitored
continuously.) However, the test results were interesting in
that 6 of 15 patients with sick sinus syndrome and intact
AV conduction had absent VA conduction. Of the 27 pa-
tients tested, 13 displayed intact VA conduction with a mean
conduction time of 240 ms (range 155 to 420) (Table 8).
The committed ventricular output of the Biotronik Diplos
pacemaker, although at times causing confusing electro-
cardiograms, produced no postoperative problems, but again
there had been a certain preselection of patients who had
ample P and R wave amplitudes because of the limited range
of sensitivity programming available with this pacemaker.*
Pacemaker arrhythmias. A number of annoyances,
rather than serious problems, developed in this series of
patients, the most fascinating of which were the electro-
cardiographic eccentricities of normal pacemaker perfor-
mance (45,46). Postoperative arrhythmias and aberrancies
can be classified into three groups: eccentricities of normal
pacemaker function, arrhythmias mediated by the pace-
maker, with the pacemaker acting as either the anterograde
or retrograde limb of a reentrant loop, and primary cardiac
arrhythmias initiated by the pacemaker. With experience,
proper selection and programming of the pulse generator
helped avoid most of these problems.
Reprogramming and testing. A serious difficulty en-
*Stimulation in the atrial or ventricular vulnerable periods has produced
a few cases of atrial fibrillation (66) and one case of ventricular tachycardia
(67).
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Table 8. Ventriculoatrial Conduction Studies
Patients (no.) VA Conduction
With
Primary Diagnosis Total VA Block Patients (no.) Mean Time (rns)
Sick sinus syndrome 15 6 (40%) 9 (60tH) 220
AV block 12 8 (67%) 4 (33tH ) 262
AV = atrioventricular; VA = ventriculoatri al .
Range (rns)
155 to 250
200 to 420
countered was the time required to rep rogram and test the
pacemakers. A full programming session , even after we
became familiar with the techn iques and shortcuts , lasted
at least 15 minutes and at times was as long as I hour. Thi s
time factor and the additional complexities of record keep-
ing, pat ient education , programmer maintenance and com-
mun ication with referring phy sicians have already engen-
dered an entire ly new system of pacemaker follow-up.
It may be that as experience is ga ined with DOD unit s
and when the devices are engineered appropria tely, a set of
nominal values could be preprogrammed into the unit . re-
serving in-depth programming for optim izing pacing para-
meters and for anal yzing pacin g problems when they occur.
For example. some suggested initial parameter values for
a fic titious DDD pacer are the f ollowing:
I . Mode: ODD
2. Minimum rate: 60 beats/min
3. Maximum rate: 110 beats/min
4. Output, atrial: 5.0 V, 1.0 ms
5. Output, ventricular: 5.0 V. 1.0 ms
6. Sensing, atrial: 0.8 mV
7. Sensing, ventricular: 2.5 mV
8. Atrial tachycardia response: 2:I block. Wenckebachor fallback
9. AV delay: 180 ms
10. Atrial refractory period, including AV delay: 450 ms
II . Ventricular refractory period: 350 ms
Current indications. In summary, DOD pacemakers are
extremely useful for patients who need the atrial contribution
to enhance cardiac output. for those sufferi ng fro m the pace-
make r sy ndrome and for an unknown number of patient s
who require pacing for con vent ion al indica tions . Alth ough
the init ial cost of DOD pacing is high . its risks are low .
Because the extent of the benefit to the patient is unclear
and long-term pacemaker function and longevity are un-
known , concl us ions cannot be drawn in regard to the true
amortized cos t to the public .
Follow-up
For approximately 10 years , routine follow-up of pat ients
with implanted pacemakers was relatively simple , because
the universal sign of battery exhaustion was slowing of the
magnetic rate. The pacemaker rate was easily measured with
a digital timer and the electrocardiographic signal could be
transmitted over standa rd telephone lines to a centrally lo-
cated recei ver. Thus, many patient s could be follo wed up
in the office by the treating phy sician, or by a pac emaker
clini c or a proprietary service . Deta ils of how follow-up
clini cs operated can be found elsewhere (68-70).
Problems. New development s have rendered follow-up
much more complex and, therefore. a satisfactory follow-
up serv ice has become difficult to devise. Some of the prob -
lems include:
I. The three prevalent lithium batteries have different modes of
failure.
2. New pacemakers are designed to indicate battery depletion in
various ways. often by a sudden change of magnet rate to a
specified value.
3. Application of a magnet over some pacemakers may have
undesirable or dangerous results O Il.
4. Dual-chamber pacing produces many unusual and difficult to
interpret electrocardiograms.
5. Transmission problems can render already complex DDD
electrocardiograms unintelligible in transtelephone monitoring.
6. Pacemaker reprogramming cannot be performed safely except
as part of a thorough clinic evaluation.
7. External overdrive. at times a useful part of an evaluation
procedure. can produce serious arrhythmias with certain types
of pacemakers.
8. Telemetry functions vary among pacemakers. and the scope
of transmissible information is increasing rapidly.
9. Record keeping is difficult and may require computer assistance.
10. It is impossible to remember all programmable pacing. sensing
and telemetry functions of all the pacemakers likely to be seen
in a moderately busy practice .
II . New pacemakers will be even more complex. compounding
all of these problems.
Follow-up system. Any follow-u p system mu st have
ce rtain basic features , as prescr ibed in guide lines soo n to
be publi shed by the Inter-Society Commission for Heart
Disease Resources (Parsonnet Y, Furman S , Sm yth NPD.
Bilitch M. in preparation ). It must include the foll owing:
1. A program for pacemaker replacement and a system for im-
plementing the program
2. Instrumentation to evaluate fully every pacemaker system seen
at each center
3. A program to provide thorough verbal and written instructions
to every patient. the family or the patient' s custodian
4. A system for keeping up to date
PACING IN THE 1980s J AM COLL CARDIOL
1983:1:339-54
349
5. Regularly scheduled follow-upappointments
6. Coverage by the follow-up service 24 hours a day. 7 days a
week
7. Trained personnel to provide the service
Future developments. The transitional status of to-
day's pacemakers is obvious. and how routine follow-up
studies will be conducted in the future is uncertain. How-
ever. it is our guess that future pacemakers will incorporate
follow-up capabilities (72,73), and will be able to transmit
basic information on telemetric command for storage. pro-
cessing and display by a microcomputer. This information
will include cardiac interface data (for example. the ratio
of pacing to sensing and the type and frequency of occur-
rence of arrhythmias) and device data (identification, resid-
ual battery capacity, lead and encapsulation integrity, pro-
grammed settings, last date of programming and so forth).
Out of this confusion a more easily managed system will
arise that will fully utilize computer and microprocessor
technology (74-82) .
Cost
At what cost will this be accomplished? The price of pacing
cannot be reduced to the simple sum of the cost of hardware.
hospital and physician services and follow-up. The cost of
the pacemaker and accessory equipment has obviously in-
creased with the technologic developments (83). but device
longevity and reliability have improved greatly, and at least
one study (84) has shown that the net cost of pacing has
risen at a rate less than that of inflation. In the cost-effec-
tiveness equation (85) one must take into account the fol-
lowing factors, forgetting for a moment the issues of man-
ifest or subtle patient benefit:
I. The reduced need for pacemaker replacement. although our
data (86) show that reoperation for pacing problems still ac-
counts for 55% of all pacemaker operations.
2. The avoidance of reoperation by pacemaker reprogramming
(86). Ourstudies and those of others (85-88) show that 17 to
25% of reoperations may be avoided by judicious use of re-
programming. This fi gure may prove much higher when we
have had a chance to evaluate multiprogrammable pacemakers
more thoroughly.
3. The anticipated simplifi cation of pacemaker follow-up by the
use of telemetry and computer technology.
4. The effects of inflation .
Discussion
The Issue of Need
Several aspects concerning the need for a pacemakerrequire
analysis: 1) Is a pacemaker needed at all? 2) Ifa pacemaker
is necessary, do we need multiprogrammability rather than
simple programming of rate and output? 3) Ifa pacemaker
is necessary, do we need to maintain AV synchrony?
Do we need multiprogrammability? This question has
been discussed earlier in this report. The advantages of
multiprogrammability over simple programming are still being
debated (40). Those opposed to multiprogrammability argue
that the multiprogrammable pacemaker is too complex for
most users and too expensive, and that evidence that it en-
hances patient care is inadequate. Furthermore , program-
ming capabilities have not been used in 29% of multipro-
grarnmable-pacemaker implants (1981survey). On the other
hand, it is known that reoperation may often be avoided by
reprogramming. Prudent programming increases pulse gen-
erator life. greatly aids in the diagnosis of pacing problems
and permits adjustments in pacing function at the end of
pacemaker life or during critical illness. The latter needs
have never been evaluated or quantified . Therefore, because
multiprogrammable pacemakers have not been in use very
long and no definitive study has been performed on all of
their potential advantages, it follows that the true need for
multiprogrammability is unknown. and that without such
data challenges of its value are equally baseless.
Do we need to maintain AV synchrony? The need for
AV synchrony for everyone, a " motherhood" concept, has
yet to be proved. The merits of such synchrony were already
recognized in 1911 (88), and a VAT pacemaker was de-
scribed as early as 1957 (89). Numerous investigators (90-
109) have shown the merits of AV synchrony and the hemo-
dynamic advantages of DVI over VVI pacing. Clinical ex-
perience with implantable dual-chamber pacemakers began
in 1962 (11 0- 113). Although in clinical use for 20 years,
several generations of the Cordis Atricor never attained great
popularity because of their large size and short life expec-
tancy, as well as the instability of the atrial electrode. The
bifocal demand pacer was similarly unpopular. although in
the past few years at least one model has been more widely
accepted (Medtronic Byrei). Even so, the 1978 survey (4)
revealed that less than 4% of the pacemakers implanted in
the United States made any use of the atrium. either for
single-chamber atrial pacing alone or in the VAT or DVI
modes.
The impact of the technical developments referred to
earlier is revealed by the 1981 survey, which found that
more than 12% of implants had atrial leads. The new DOD
pacemakers provide rate-responsiveness, an aspect of phys-
iologic pacing not fully available in previous units. Atrio-
ventricular synchrony is maintained at slow rates by pacing
both chambers sequentially, and at fast atrial rates by track-
ing the atrium up to safe preselected limits. As pointed out
by Goldreyer (114) in a recent editorial, even these pace-
makers are not entirely " physiologic," particularly at ab-
normally fast atrial rates when the atrium and ventricle may
contract simultaneously.
The question ofneed remains: Do all patientsexcept those
with frequent supraventricular tachycardia or atrial fibril-
lation need AV synchrony?Cohen and Frank (115) estimate
that 7% of their patients will need dual-chamber pacing;
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TabIe~. Indexes of Pacing Effectiveness
Preimplant Condition
Stokes-Adams seizures in association
with fixed or intermittent complete
heart block
Cerebral symptoms (syncope,
dizziness, weakness, confusion)
secondary to bradyarrhythmias
Cerebral symptoms secondary to
suspected, but unproved,
conduction disorder
Symptomatic organ failure secondary
to bradycardia, complete heart
block, etc.
Palpitation or collapse due to
supraventricular or ventricular
tachycardia
Prophylactic pacing after recovery
from acute myocardial infarction
and complete heart block
Bi- or trifascicular block and
prolonged HV interval
Bi- or trifascicular block alone
AV = atrioventricular.
Cessation
of Symptoms
Yes
Yes
Yes
Yes
Yes
Prolongation
of Life
Yes
?
?
?
?
?
?
Improved Quality
of Life
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Comment
The only situation where increased
longevity can be proved.
Restoration of AV synchrony may at times
be helpful, but supporting data are
needed. Evidence that life will be
prolonged is lacking.
There are some proponents for this.
Controversial topic.
There are some proponents for this.
Controversial topic.
There are some proponents for this.
Controversial topic.
others (64,116.117) estimate that 26 to 85% of their patients
will need it.* Is the need for AV synchrony based on the
degree of ventricular dysfunction, the desirability of a large
rate range in athletic persons, the avoidance of the pace-
maker syndrome or the enhancement of exercise tolerance?
Do we know the optimal AV delay in all patients? Will a
sedentary 71 year old patient perceive the advantage of an
AV synchronous pacemaker?
Pacemaker Indications
The indication for permanent pacemaker implantation two
decades ago was clear-cut. However, pacemakers today are
used for bradyarrhythmias of many causes, abnormalities
of impulse formation and propagation, drug-induced bra-
dycardias, prevention or interruption of tachyarrhythmias
and prophylaxis in certain types of electrocardiographic ab-
normalities (l18, 119). In order to define the indications and
prove that pacing is beneficial, symptoms and signs indic-
ative of improved quality of life must be identified. En-
hanced longevity is not the sole index of successful treat-
ment. Herein lies the central problem in the current controversy
over needless pacing: Once a permanent pacemaker is im-
planted, how can one tell that the implantation has done
any good, has changed the quality of life or has provided
some other nonspecific benefit? From the expected benefits
*In our own practice, 67.2% (171 of 278) of new implants during the
18 month period ending in July 1982 were dual-chamber systems. as were
40.5% (40 of 101) of replacements for single-chamber pacemakers.
of pacing (Table 9); it is obvious that some of the necessary
judgments are so subjective that it is difficult to be sure
whether a desired result was obtained.
It might be that acceptable indications can be found only
by a study of common practice patterns for the "mix" of
indications, in much the same manner that peer review groups
analyze an operation. Even with appendectomy, where the
pathologic specimen is a clear index of diagnostic accuracy,
surgeons are permitted a 10 to 15% "error" in diagnosis.
In the absence of clear end points. as is the case in cardiac
pacing. one must look for help elsewhere.
Current indications. The 1981 survey sheds some light
on the mix of indications (Table 10). The enormous standard
deviation in each listed category suggests that the use of
precedents as standards will be of limited value. High-grade
AV block. a widely accepted indication for pacemaker im-
plantation, was the primary indication for pacing in about
42% of patients, and sick sinus syndrome was the primary
indication in about 51%. In the remaining instances, im-
plantation was performed for drug-induced bradycardia, hy-
persensitive carotid sinus, tachycardia and other conditions.
Of the patients who received implants, 14% were asymp-
tomatic. Should these percentages be accepted as standards,
and implanters whose mix deviates from them be subject to
peet review?
Longevity after pacemaker implantation. The re-
quirement that pacemaker patients be symptomatic has been
implicit in many recent criticisms (5,12,120- I22), although
many investigators have found valid indications for pacing
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Table 10. Indications for Primary Pacemaker Implant. 1982
in a variety of conditions in which the patients are often
asymptomatic (123-135). Except in patients with complete
heart block and Stokes-Adams seizures. there is no strong
evidence that pacing prolongs life. In other situations. length
of life after pacemaker implantation is affected primarily by
the patient's age and the presence of such conditions as
congestive heart failure, diabetes mellitus, stroke and renal
failure, and not by the electrocardiographic diagnosis (136-
138).
Indications in asymptomatic patients. It IS with the
asymptomatic patient that the real controversy arises. The
management of sick sinus syndrome is a case in point. For
a patient with sinus bradycardia and occasional sinus pauses,
but few or no symptoms, a complete workup including
ambulatory electrocardiographic monitoring and echocar-
diography, a thallium stress test and a comprehensive elec-
trophysiologic study will cost at least $3,000 and entail some
risks. If the patient may be safely assumed to be otherwise
healthy, the virtually risk-free prophylactic implantation of
an AAI pacemaker represents an effective and economical
clinical solution.
The proper choice requires judgment. Is the decision to
implant a pacemaker wise and in the best interest of the
patient? Is implaritation of a pacemaker needless surgery?
Will a se~ond opinion. or five opinions, help in the decision-
making process? The point is that there are no unequivocally
"correct" answers. But a peer reviewer might question a
discharge diagnosis of "sick sinus syndrome, sinus bra-
dycardia and pause," and would surely examine a physi-
cian's work more closely if 90% of his cases were of this
type.
Areas of conflicting opinions. Items 6 to 8 in Table 9
bear similar scrutiny because of conflicting viewpoints on
the risks of certain electrocardiographic abnormalities that
can be associated with sudden death. such as various bundle
branch block patterns with prolongation of the HV interval,
and transient complete heart block secondary to myocardial
infarction. An argument can be made for or against im-
plantation in each of these situations (130,132-
134.136,139,140). but on an individual basis, the decision
to implant a pacemaker rests with the balanced judgment
and wisdom of the physician. Although some have favored
compulsory second opinions, almost everyone agrees that
all aspects of pacing should be managed only by qualified
specialists (17,86,120,141-144).
Indication
Sinus node dysfunction
Atrioventricular block
Tachyarrhythmia
Other
SD = standard deviation.
Mean (%)
51.3
41.7
0.8
6.0
SD (%)
22.5
21.8
3.1
8.0
Such is the state ofpacing in the 1980s: an array of devices
of unproved usefulness, arrhythmias of uncertain prognosis,
a growing body of knowledge. changing attitudes and many
challenges.
Addendum
Scherlis and Dembo (145) recently reviewed the complete
medical records of 576 of the 817 patients whose pacemaker
implantations had been adjudged unnecessary or question-
able by Greenberg et al. (5) as reported in the national press.
It was found that many serious errors had been made in the
earlier study. including errors in coding of diagnoses (11.6%)
and surgical procedures (12.8%). Utilizing the criteria set
forth by the earlier investigators, they found only 26 un-
necessary or questionable implantations. If pacemaker im-
plantation for "ventricular overdrive" was considered jus-
tified. only 18 unnecessary or questionable cases remained.
Thus, after reviewing the charts of 70.5% of the same
patients, the investigators estimated that only 3.1 to 4.5%
of the 817 implantations cited in the earlier study were in
fact unnecessary or questionable, implying that only 1.1 to
1.7% of the 2.222 implantations originally studied were
unnecessary or questionable.
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